Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder
Completed · Phase 3 · Has a placebo group
Conditions studied: Irritability Associated With Autism Spectrum Disorder (ASD)
In brief
The purpose of this study is to find out about the potential benefits and safety of brexpiprazole in children and adolescent participants, aged 5 to 17, with irritability associated with autism spectrum disorder.
Key facts
- Study ID
- NCT04174365
- Run by
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- People needed
- 119
- Starts
- 2019-10-30
- Expected to finish
- 2022-09-09
- Last updated by the study team
- 2025-08-28
Who can join
Age: 5 and older, up to 17. Sex: any. Healthy volunteers: not accepted.
Where it is running
- For additional information regarding sites — Princeton, New Jersey, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.